tiprankstipranks
Trending News
More News >
Advertisement

GRPZ - ETF AI Analysis

Compare

Top Page

GRPZ

Invesco S&P SmallCap 600 GARP ETF (GRPZ)

Rating:74Outperform
Price Target:
GRPZ, the Invesco S&P SmallCap 600 GARP ETF, has a solid overall rating driven mainly by strong, growing companies like Catalyst Pharma, Krystal Biotech, and Tidewater, which show healthy financial performance, positive outlooks, and supportive technical trends. Some holdings, such as DXP Enterprises and UFP Technologies, introduce a bit more risk due to bearish or mixed technical signals and operational challenges, but these are balanced by the broader group of financially sound, strategically focused stocks. The main risk factor is that many top holdings are smaller, niche companies whose performance can be more volatile and sensitive to short-term business or market shifts.
Positive Factors
Strong Recent Performance
The ETF has shown solid gains so far this year and over the last few months, indicating positive recent momentum.
Leading Holdings Performing Well
Most of the top 10 stocks, such as Powell Industries and several health care names, have delivered strong year-to-date results that support the fund’s returns.
Broad Sector Diversification
Holdings are spread across financials, health care, industrials, consumer sectors, energy, and technology, which helps reduce the impact of weakness in any single industry.
Negative Factors
Small Fund Size
The ETF manages a relatively small amount of assets, which can sometimes lead to higher trading costs and less liquidity for investors.
Higher-Than-Core Expense Ratio
The fund’s fee is noticeably higher than many broad market index ETFs, which can slightly reduce long-term returns.
Heavy U.S. and Sector Focus
With almost all exposure in U.S. stocks and a large tilt toward financials and health care, the fund is vulnerable if these areas of the market struggle.

GRPZ vs. SPDR S&P 500 ETF (SPY)

GRPZ Summary

GRPZ is an ETF that follows the S&P SmallCap 600 GARP Index, focusing on smaller U.S. companies that are growing but still reasonably priced. It holds a mix of sectors like financials, health care, and industrials, with examples including Krystal Biotech and Axos Financial. Someone might invest in GRPZ to seek long-term growth and diversify beyond large, well-known stocks by tapping into the potential of smaller, more agile businesses. A key risk is that small-cap stocks can be more volatile, so the ETF’s price can move up and down more sharply than the overall market.
How much will it cost me?The Invesco S&P SmallCap 600 GARP ETF (GRPZ) has an expense ratio of 0.35%, which means you’ll pay $3.50 per year for every $1,000 invested. This cost is slightly higher than average for ETFs because it tracks a specific index with a focus on small-cap companies and uses a more selective strategy. It’s still relatively affordable compared to actively managed funds.
What would affect this ETF?GRPZ could benefit from economic growth in the U.S., as small-cap companies often thrive during periods of expansion and innovation, particularly in sectors like Industrials and Technology, which are heavily weighted in the ETF. However, rising interest rates or economic slowdowns could negatively impact small-cap stocks, as these companies may face higher borrowing costs and reduced consumer demand, especially in sectors like Consumer Cyclical and Financials. Regulatory changes or shifts in energy policies could also affect holdings like Helmerich & Payne and International Seaways in the Energy sector.

GRPZ Top 10 Holdings

GRPZ is leaning hard into U.S. small-cap growth stories, with a noticeable tilt toward health care innovators and niche industrial and energy players. Krystal Biotech and TransMedics are two of the fund’s rising stars, helping power returns as their growth narratives gain traction. On the industrial and energy side, Powell Industries, Tidewater, and Cactus are also pulling their weight, adding steady momentum. Catalyst Pharma has been more mixed lately, occasionally losing steam, but overall the fund’s performance is being driven by a broad cast of U.S.-focused small-cap winners rather than a single dominant name.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Powell Industries2.49%$72.55K$7.10B174.19%
76
Outperform
International Seaways2.07%$60.18K$3.16B67.28%
72
Outperform
Tidewater1.94%$56.50K$3.47B28.57%
78
Outperform
Krystal Biotech1.82%$53.08K$8.02B80.40%
80
Outperform
DXP Enterprises1.81%$52.59K$2.33B45.25%
71
Outperform
Worthington Steel, Inc.1.80%$52.34K$2.38B63.13%
77
Outperform
Cactus1.74%$50.78K$4.55B-5.15%
77
Outperform
Catalyst Pharma1.72%$50.10K$2.99B4.56%
83
Outperform
AZZ1.71%$49.79K$4.19B43.18%
79
Outperform
Ufp Technologies1.65%$48.18K$1.90B-4.55%
75
Outperform

GRPZ Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
27.94
Positive
100DMA
27.09
Positive
200DMA
26.14
Positive
Market Momentum
MACD
0.38
Negative
RSI
59.99
Neutral
STOCH
66.81
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GRPZ, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 28.64, equal to the 50-day MA of 27.94, and equal to the 200-day MA of 26.14, indicating a bullish trend. The MACD of 0.38 indicates Negative momentum. The RSI at 59.99 is Neutral, neither overbought nor oversold. The STOCH value of 66.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GRPZ.

GRPZ Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$2.88M0.35%
$99.71M0.45%
$80.54M0.75%
$75.03M0.04%
$74.06M0.18%
$69.60M0.35%
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GRPZ
Invesco S&P SmallCap 600 GARP ETF
29.12
3.39
13.18%
FSML
Franklin Small Cap Enhanced ETF
AFSM
First Trust Active Factor Small Cap ETF
BKSE
BNY Mellon US Small Cap Core Equity ETF
STXK
Strive 2000 ETF
FLQS
Franklin LibertyQ U.S. Small Cap Equity ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement